Abstract 117P
Background
Radiofrequency ablation (RFA) helps to achieve R0 resection and may provide an alternative treatment for patients with unresectable colorectal liver metastases (CRLM) in combination with surgical resection. However, researches on efficacy and complication risks of hepatectomy combined with intraoperative RFA for multiple colorectal liver metastases (mCRLM) are limited.
Methods
From January 2013 and March 2017, patients who underwent hepatectomy alone (HA cohort) or hepatectomy combined with intraoperative RFA (HIR cohort) for mCRLM were retrospectively identified from Zhongshan Hospital affiliated to Fudan University. The mCRLM patients that were given ‘hepatectomy combined with intraoperative RFA’ were matched with those treated with hepatectomy alone via 1:1 propensity score (PS) matching. Recurrence-free survival (RFS) and overall survival (OS) after the initial hepatectomy were compared.
Results
After PSM, 252 patients were included (126 in each group). The HIR cohort had more grade I complications while no difference in higher grade complications (p = 0.231) and postoperative morbidity(p = 0.534) was detected. Total recurrence which includes intrahepatic and extrahepatic recurrence was no significantly difference in HIR cohort compared to HA cohort (p = 0.320). The median total RFS for HIG and HA was 10.47months and 10.7 months respectively (HR = 1.086 95% CI 0.766-1.540). The median OS for HIG and HA was 43.9 months and 46.1 months respectively (HR = 0.986 95% CI 0.648-1.307).
Conclusions
Hepatectomy combined with intraoperative RFA can be safely performed in mCRLM patients without an increased severe risk in the procedure and is representing a beneficial treatment to otherwise inoperable patients. The outcome of hepatectomy combined with intraoperative RFA is even comparable to hepatectomy alone after propensity score matching.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract